What Happened?
Cambridge, MA-based Q32-Bio Appointed Michael Broxson as Chief Executive Officer
About the Company
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
About the Person
Michael Broxson is Chief Executive Officer at Q32 Bio. Previously, Michael held various senior HR leadership roles in the industry.
Info Source
News
Short Profile